Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

1 - 10of about 641 News

September 20, 2021

Not intended for U.S. and UK Media

Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease

September 16, 2021

Not intended for U.S. and UK Media – ESMO Congress 2021:

Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer

September 09, 2021

Not intended for U.S. and UK Media

Bayer to highlight expanded research from growing oncology portfolio at ESMO Congress 2021

September 06, 2021

Not intended for U.S. and UK Media

Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough

August 31, 2021

Not intended for U.S. and UK Media

Bayer starts Phase III clinical development program OASIS with Elinzanetant

August 28, 2021

Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021

New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression